Network Pharmacology of Astragalus-Rhizoma Saposhnikovia divaricata drug pair in the treatment of COVID-19

doi:10.19803/j.1672-8629.2022.04.11

Abstract

Abstract: Objective To investigate the pharmacological mechanism of Astragalus-Rhizoma Saposhnikovia divaricata against Covid-19. Methods The effective components and related target protein of Astragalus-Rhizoma and Saposhnikovia divaricata were screened via the Traditional Chinese Medicine Systems Pharmacology (TCMSP) analysis platform. An effective compound- target protein visual network was established using Cytoscape software, and topology analysis was performed. The targets related to COVID-19 were found via the GeneCards online analysis platform. The core targets were selected by the Venny platform, and a protein-protein interaction (PPI) network of the core targets was constructed and analyzed by STRING database. GO (Gene Ontology) enrichment and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment of target protein coding genes were performed using DAVID database. Results A total of thirty-six types of effective compounds which included quercetin, kaempferol and wogonin, 215 targets and 59 core targets which included VEGFA, IL-6, TNF, TP53 and MAPK8 were selected. GO functional enrichment analysis obtained 286 GO items (P<0.05), while KEGG pathway enrichment analysis obtained 97 pathways related to COVID-19 P<0.05), involving cancer signaling pathways, HIF-1 and Toll like signaling pathways. Conclusion The active compounds in Astragalus-Rhizoma Saposhnikovia divaricata drug pair can exert a preventive or therapeutic effect on COVID-19 by means of multiple components, multiple targets and multiple pathways.

Key words: Astragalus-Rhizoma, Saposhnikovia divaricata, novel coronavirus pneumonia, network pharmacology

CLC Number:

R978.7

WU Zuomin, YANG Juan, WANG Longlong, WANG Rui. Network Pharmacology of Astragalus-Rhizoma Saposhnikovia divaricata drug pair in the treatment of COVID-19[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 395-399.

References

[1] KICKBUSCH I, LEUNG G.Response to the emerging novel coronavirus outbreak[J]. BMJ, 2020, 368: m406.
[2] WU YZ, ZHOU Q, XUE Y, et al.Research progress of antivirus therapy of COVID-19: a review of clinical trials[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2020, 40(20): 2184-2190.
[3] YANG P, LI J, AN W.Adverse drug reactions in 45 Patients with COVID-19[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(5): 272-275.
[4] HUANG YY, HU JQ, LU HR, et al.Overview of Theory About Pathogenesis,Prevention and Treatment of Epidemic Diseases in Inner Canon of Huangdi[J]. Journal of Basic Chinese Medicine(中国中医基础医学杂志), 2020, 26(04): 421-423, 429.
[5] YANG ZJ, YE L, CHEN L, et al.Treatment of COVID-19 with Qi Gui Ling mixture[J]. Acta Chinese Medicine(中医学报), 2020, 35(6): 1151-1153, 1176.
[6] CUI XS, JI LM, FU H, et al.A case of novel coronavirus pneumonia patients treated by Yupingfeng powder[J]. Hubei Journal of Traditional Chinese Medicine(湖北中医杂志), 2021, 43(1): 11-13.
[7] PING XH, XU HL, FU DF, et al.Clinical observation of Jiawei Yupingfeng powder combined with western medicine in the treatment of the novel coronavirus pneumonia[J]. The Medical Forum(基层医学论坛), 2021, 25(2): 149-151.
[8] JIANG PF, LI SN, LIU PEI, et al.Analysis of TCM prevention and treatment schemes for COVID-19 in various regions of China[J]. Acta Chinese Medicine(中医学报), 2020, 35(4): 709-719.
[9] JIANG W, JIANG SL, LIU P.Research Progress on pharmacologic effects of astragaloside IV[J]. Chinese Archives of Traditional Chinese Medicine(中华中医药学刊), 2019, 37(9): 2121-2124.
[10] GUO Z, ZOU J, ZHANG X, et al.Anti-inflammatory effect of total flavonoids of astragalus in vivo[J]. Progress in Veterinary Medicine(动物医学进展), 2015, 36(9): 64-66.
[11] LIU SL, JIANG CX, ZHAO Y, et al.Advance in study on chemical constituents of Saposhnikovia divaricate and their pharmacological effects[J]. Chinese Traditional and Herbal Drugs(中草药), 2017, 48(10): 2146-2152.
[12] GAO H, BAI CC, PANG M, et al.The new febrile disease originated in Su Wen[J]. Global Traditional Chinese Medicine, 2018, 11(11): 1740-1742.
[13] JO S, KIM H, KIM S, et al.Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors[J]. Chemical Biology & Drug Design, 2019, 94(6): 2023-2030.
[14] YAO YX, HE ZX, LIU XF, et al.Potential material basis of Kangbingdu Granules for treatment of coronavirus disease 2019(COVID-19) based on network pharmacology and molecular docking technology[J]. Chinese Traditional and Herbal Drugs(中草药), 2020, 51(6): 1386-1396.
[15] HUAN Y.Neuroprotective effects of kaempferol against 2VO-induced chronic cerebral ischemia in rats[J]. Chinese Journal of Pharmacology and Toxicology(中国药理学与毒理学), 2016, 30(10): 1028-1029.
[16] WU Y, JIN YZ, ZHANG S, et al.Effect and mechanism of wogonin on NF-κB nuclear translocation and expression in NR8383 cells infected by influenza virus[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志) , 2012, 18(18): 161-165.
[17] CHEKALINA NI, SHUT SV, TRYBRAT TA, et al.Effect of quercetin on parameters of central hemodynamics and myocardial ischemia in patients with stable coronary heart disease[J]. Wiad Lek, 2017, 70(4): 707-711.
[18] LI JC.Investigation on the absorption, metabolism mechanism of wogonin[D]. Hefei: Anhui Medical University(安徽医科大学), 2010.
[19] JIAN, GEORGE L, LEILEI C, et al.Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-Kappa B induced matrix metalloproteinase 9 expression[J]. Plos One, 2012, 7(9): e46264.
[20] CHEN AY, WANG LQ, SHEN ZT, et al.Study of relationship between the serum levels of IL-6, IL-10, IL-17, IL-33 and radiation induced lung injury in patients with esophageal cancer[J]. Oncology Progress(癌症进展), 2019, 17(23): 2825-2829.
[21] ZHANG Y, ZHOU DM, LI WEI,et al.The expression level of TNF-αin patients with painful diabetic neuropathy[J]. Chinese Journal of Laboratory Diagnosis(中国实验诊断学), 2020, 24(1): 36-40.
[22] HUANG CB, WAN L, LIU J, et al.Correlation of cardiopulmonary dysfunction with activation of NF-κBp65/TNF-α and TGF-β1/Smads signaling pathways in rats with adjuvant arthritis[J]. Immunological Journal(免疫学杂志), 2014, 30(5): 382-386.
[23] LIANG J, YUAN S, WANG X, et al.Attenuation of pristimerin on TNF-α-induced endothelial inflammation[J]. International Immunopharmacology, 2020, 82(5): 106326.
[24] PANTEVA M, KORKAYA H, JAMEEL S.Hepatitis viruses and the MAPK pathway: is this a survival strategy?[J]. Virus Research, 2003, 92(2): 131-140.
[25] LIM YX, NG YL, TAM JP, et al.Human coronaviruses: a review of virus-host interactions[J]. Diseases, 2016, 4(3): 26.
[26] DESHMANE SL, AMINI S, SEN S, et al.Regulation of the HIV-1 promoter by HIF-1α and Vpr proteins[J]. Virology Journal, 2011, 8(1): 477.
[27] LI QY, FENG RF, QIAO ZL, et al.Role of hypoxia-inducible factor-1 (HIF-1) in virus infection[J]. Journal of Microbiology(微生物学杂志), 2014, 34(1): 88-91.
[28] CAI J, LI HX, LIU MY, et al.Safe use of lopinavir/ritonavir for COVID-19 based on literature analysis of adverse reactions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(6): 326-331.